

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Required to respond to a collection of information unless it contains a valid OMB

PTO/SB/05A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<div> <div> <div>ENTER 1003</div> </div> </div>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/091,709
				Filing Date	March 5, 2002
				First Named Inventor	Gallaher
				Art Unit	1614
				Examiner Name	
Sheet	1	of	3	Attorney Docket Number	RNBO-1-1003


[illegible][illegible]

Examiner Signature	R. Teller	Date Considered	6/4/03
-----------------------	-----------	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/088 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO		Complete if Known			
		Application Number	10/091,709		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	March 5, 2002		
		First Named Inventor	Gallaher		
		Group Art Unit	1614		
		Examiner Name			
Sheet	2	of	3	Attorney Docket Number	RNBO-1-1003

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ²	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RT	01	NORRILD et al., "Organization of Cytoskeleton Elements during Herpes Simplex Virus Type 1 Infection of Human Fibroblasts: An Immunofluorescence Study", J. Gen. Virol. (1986), pgs. 97-105, Vol. 67	
	02	KRISTENSSON et al., "Neuritic Transport of Herpes Simplex Virus in Rat Sensory Neurons in vitro. Effects of Substances Interacting with Microtubular Function and Axonal Flow [Nocodazole, Taxol and Erythro-9-3-(2-hydroxynonyl)adenine], J. Gen. Virol. (1986), pgs. 2023-2028	
	03	BALL et al., "Taxol Inhibits Stimulation of Cell DNA Synthesis by Human Cytomegalovirus", Experimental Cell Research (1990), pgs. 37-44, Vol. 191	
	04	ALBERTS, et al., "Chapter 16. The Cytoskeleton", Molecular Biology of the Cell, 3rd edn. Part III. Internal Organization of the Cell, (1994), pgs. 1-10	
	05	KOGA-BAN Y et al., "6 cDNA sequences of three kinds of beta-tubulins from rice", (1995), pgs. 21-26, DNA Res 2(a)	
	06	ZHOU et al., "Early Phase in the Infection of Cultured Cells with Papillomavirus Virions", Virology 214 (1995), pgs. 167-176	
	07	HUNG et al., "Discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks taxol binding and results in mitotic arrest", Chemistry & Biology 3(4): (1996), pgs. 287-293	
	08	KOWALSKI et al., "The Microtubule-Stabilizing Agent Discodermolide Competitively Inhibits the Binding of Paclitaxel (Taxol) to Tubulin Polymers, Enhances Tubulin Nucleation Reactions More Potently than Paclitaxel, and Inhibits the Growth of Paclitaxel-Resistant Cells, Molecular Pharmacology (1997), pgs. 613-622, Vol. 52	
	09	SODEIK et al., "Microtubule-mediated Transport of Incoming Herpes Simplex Virus 1 Capsids to the Nucleus", The Journal of Cell Biology (March 10, 1997), pgs. 1007-1021, Vol. 136	
	10	LONG et al., "Eleutherobin, a Novel Cytotoxic Agent That Induces Tubulin Polymerization, Is Similar to Paclitaxel (Taxol)", Advances in Brief (October 30, 1997), pgs. 1111-1115	
	11	OJIMA et al., "A common pharmacophore for cytotoxic natural products that stabilize microtubules", Proc. Natl. Acad. Sci, USA (April 1999), pgs. 4256-4261, Vol. 96	

Examiner Signature	R. Teller	Date Considered	6/4/03
---------------------------	-----------	------------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/091,709		
		Filing Date	March 5, 2002		
		First Named Inventor	Gallagher		
		Group Art Unit	1614		
		Examiner Name			
Sheet	3	of	3	Attorney Docket Number	RNBO-1-1003

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RT	12	LIU et al., "Association of Bovine Papillomavirus Type 1 with Microtubules", Virology 282, (August 17, 2000), pgs. 237-244	
	13	SODEIK, "Mechanisms of viral transport in the cytoplasm", Trends in Microbiology, (October 2000), 465-472, Vol. 8, No. 10	
	14	JORDAN, "Mechanism of action of anti-tumor drugs that interact with microtubules and tubulin", Current Medicinal Chemistry-Anti-Cancer Agents, (2002), Vol. 2, No. 1	
	15	DUFLOS, Novel aspects of natural and modified vinca alkaloids", Current Medicinal Chemistry-Anti-Cancer Agents, (2002), Vol. 2, No. 1	
	16	DESBENE et al., "Drugs that inhibit tubulin polymerization: The particular case of podophyllotoxin and analogues", Current Medicinal Chemistry-Anti-Cancer Agents, (2002), Vol. 2, No. 1	
	17	JIMINEZ-BARBERO et al., "The solid state, solution and tubulin-bound conformations of agents that promote microtubule stabilization", Current Medicinal Chemistry-Anti-Cancer Agents, (2002), Vol. 2, No. 1	
	18	WARTMANN et al., "The biology and medicinal chemistry of epothilones", Current Medicinal Chemistry-Anti-Cancer Agents, (2002), Vol. 2, No. 1	
	19	LODISH et al., "Chapter 19. Cell Motility and Shape II: Microtubules and Intermediate filaments", Current Medicinal Chemistry-Anti-Cancer Agents, (2002), Vol. 2, No. 1	
	20	KOTSAKIS et al., "Microtubule Reorganization during Herpes Simplex Virus Type 1 Infection Facilitates the Nuclear Localization of VP22, a Major Virion Tegument Protein", Journal of Virology, (September 2001), pgs. 8697-8711	

Examiner Signature	R. Toller	Date Considered	6/4/03
--------------------	-----------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.